Table 2.
Cancer types across all treatment groups out to 20 years after randomization
| Cancer Type | AP | CY | WDL | Total |
|---|---|---|---|---|
| NSC | ||||
| total recipients | 29 | 35 | 31 | 95 |
| adenocarcinoma | 8 | 15 | 12 | 35 |
| colon | 4 | 4 | 1 | 9 |
| prostate | 0 | 3 | 2 | 5 |
| kidney | 0 | 2 | 1 | 3 |
| breast | 0 | 1 | 2 | 3 |
| esophagus/stomach | 1 | 1 | 1 | 3 |
| other sites | 3 | 3 | 2 | 8 |
| unknown primary | 0 | 1 | 3 | 4 |
| squamous cell carcinoma | 4 | 11 | 4 | 19 |
| cervix | 1 | 3 | 0 | 4 |
| lung | 0 | 3 | 1 | 4 |
| head and neck | 2 | 3 | 3 | 8 |
| other | 1 | 2 | 0 | 3 |
| melanoma | 7 | 1 | 1 | 9 |
| lymphoma (all) | 2 | 3 | 4 | 9 |
| leukemia | 1 | 0 | 1 | 2 |
| transitional cell carcinoma | 3 | 0 | 2 | 5 |
| Kaposi | 0 | 1 | 1 | 2 |
| multiple myeloma | 1 | 0 | 0 | 1 |
| other/unknown | 3 | 4 | 6 | 13 |
| Skin cancer | ||||
| total recipients | 51 | 65 | 55 | 171 |
| squamous cell carcinoma | 32 | 36 | 34 | 102 |
| basal cell carcinoma | 19 | 28 | 21 | 68 |
| other | 0 | 1 | 0 | 1 |